As member of drug development project teams, contributed to drug development strategies as well as accelerated and streamlined drug development by applying
model-informed drug development approaches strategically and hands-on in the therapeutic area respiratory
Led regulatory submission relevant dose-exposure-response analyses comprising disease progress modeling, time-to-event analysis, and covariate analysis for
nintedanib in idiopathic pulmonary fibrosis
Evaluated of approaches, models, and software programs for modeling and simulation of respiratory diseases including pharmaceutical intervention and
pharmaco-economics
